NEW YORK (GenomeWeb) – Response Genetics has filed a shelf registration with the US Securities and Exchange Commission to offer up to $20 million in securities from time to time.
Securities that may be offered include Response's common stock, preferred stock, and warrants, the company said in its SEC document. Proceeds from any offering will go toward general corporate purposes, such as the funding of its operations, working capital, R&D efforts, capital expenditures, and strategic investments.
In December, Response launched a $4.8 million public offering of its common stock.
Late last month, the Los Angeles-based molecular diagnostics firm said that it received a warning letter from the Nasdaq that its shares had closed below a minimum $1 per share for 30 consecutive business day, putting Response in jeopardy of having its stock delisted from the Nasdaq Capital Market. The firm has until Dec. 17 to regain compliance.